Improving the lives of patients is what drives us
Over the past four decades, Ipsen has cemented a strong presence in the UK, currently employing 750 professionals across three sites: Oxford (Milton Park), Slough, and Wrexham.
Our organisation spans the entire value chain in the UK: research and development (R&D), manufacturing and distribution, plus commercial operations. The UK contributes significantly to our business, with global specialised toxin production taking place at our site in Wrexham, research programmes being conducted at Milton Park, and a range of commercial and corporate activities and functions housed in our Slough site.
Ipsen UK Achievements 2022
Ipsen UK & Ireland received a Great Place to Work Accreditation for 2021!
Ipsen achieved the 2021 Great Place to Work accreditation for UK & Ireland Operations, UK Slough and UK Milton Park, Oxford. The independently awarded accreditation has been received following feedback from more than 300 colleagues.
Wrexham uses 100% aims to reduce carbon intensity by 50% by 2025.
Ipsen Wrexham is the first site in the UK & Ireland to use 100% renewable power, with the aspiration that the site will support the production and export of Ipsen medicines across the world in a sustainable manner. Currently, further investment and expansion of the site is being explored, with a potential for a Science Academy.
The Didcot Powerhouse Fund
The Didcot Powerhouse Fund was launched in January 2022, with our Milton Park site committing to the initiative. The fund was founded to address inequality in Didcot, a town that has a mixed profile of neighbourhoods where affluent areas adjoin those with greater need.
Our sites in the UK
At Ipsen, we strive to be a creative and like-minded partner of choice. We believe that achieving the best results for patients depends on our ability to work effectively and ethically in partnership with those around us, including healthcare professionals, the NHS, patient groups, policy makers and government.